Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.70 |
| ▸ | DRD3 | P35462 | 8/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 4/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | DRD5 | P21918 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7353465 | 0.84 | DRD2 (0.81) | DRD2DRD3KCNH2DRD1DRD4 | |
| SCHEMBL8437990 | 0.84 | DRD2 (0.81) | DRD2DRD3KCNH2DRD1DRD4 | |
| SCHEMBL2861863 | 0.82 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2861859 | 0.82 | DRD2 (1.00) | DRD2DRD3DRD1DRD4DRD5 | |
| Ammonia Solution, Strong SCHEMBL7206823 | 0.81 | DRD2 (0.97) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL11627187 | 0.81 | DRD2 (0.55) | DRD2DRD3DRD1DRD4DRD5 | |
| Bromide SCHEMBL7314081 | 0.81 | DRD2 (0.97) | DRD2DRD3DRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL7317357 | 0.81 | DRD2 (0.97) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7822642 | 0.81 | DRD2 (0.72) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL7349653 | 0.81 | DRD3 (0.67) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |